216 related articles for article (PubMed ID: 33403010)
1. Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis.
Chen H; Horita N; Ito K; Nagakura H; Hara Y; Kobayash N; Yamamoto M; Kudo M; Kaneko T
Ther Adv Med Oncol; 2020; 12():1758835920965841. PubMed ID: 33403010
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
Du J; Wang X; Fan L; Shan X; Li M; Liu L
Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
[TBL] [Abstract][Full Text] [Related]
3. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Mathieu L; Shah S; Pai-Scherf L; Larkins E; Vallejo J; Li X; Rodriguez L; Mishra-Kalyani P; Goldberg KB; Kluetz PG; Theoret MR; Beaver JA; Pazdur R; Singh H
Oncologist; 2021 May; 26(5):433-438. PubMed ID: 33687763
[TBL] [Abstract][Full Text] [Related]
5. The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.
Horita N; Nagashima A; Nakashima K; Shibata Y; Ito K; Goto A; Yamanaka T; Kaneko T
Sci Rep; 2017 Oct; 7(1):13185. PubMed ID: 29030633
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
7. First-line immune-checkpoint inhibitor treatment in extensive-disease small-cell lung cancer: A classical and network meta-analysis.
Mutlu H; Bozcuk H; Artaç M; Eser İ
J Cancer Res Ther; 2023 Apr; 19(Supplement):S6-S11. PubMed ID: 37147977
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang L; Huang R; Chu Z; Zhan Q
J Thorac Oncol; 2010 Jun; 5(6):867-73. PubMed ID: 20521354
[TBL] [Abstract][Full Text] [Related]
12. Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Kim SH; Jo EJ; Mok J; Lee K; Kim KU; Park HK; Lee MK; Eom JS; Kim MH
Korean J Intern Med; 2023 Mar; 38(2):218-225. PubMed ID: 36800677
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
[TBL] [Abstract][Full Text] [Related]
14. Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Han D; Wang G; Sun L; Ren X; Shang W; Xu L; Li S
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28707433
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
Jiang S; Huang L; Zhen H; Jin P; Wang J; Hu Z
BMC Cancer; 2021 Dec; 21(1):1308. PubMed ID: 34876060
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Ishii H; Azuma K; Shimose T; Yoshioka H; Kurata T; Shingu N; Okamoto M; Kawashima Y; Okamoto I
Thorac Cancer; 2023 Jan; 14(1):105-107. PubMed ID: 36380738
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma.
Chen HL; Tu YK; Chang HM; Lee TH; Wu KL; Tsai YC; Lee MH; Yang CJ; Hung JY; Chong IW
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287455
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Xu F; Ren X; Chen Y; Li Q; Li R; Chen Y; Xia S
BMC Cancer; 2018 Aug; 18(1):808. PubMed ID: 30097029
[TBL] [Abstract][Full Text] [Related]
19. Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Chen Y; Chen L; Zhong D
Thorac Cancer; 2017 May; 8(3):170-180. PubMed ID: 28263036
[TBL] [Abstract][Full Text] [Related]
20. Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Masubuchi K; Imai H; Wasamoto S; Tsuda T; Minemura H; Nagai Y; Yamada Y; Kishikawa T; Umeda Y; Shiono A; Takechi H; Shiihara J; Kaira K; Kanazawa K; Taniguchi H; Kaburagi T; Kagamu H; Minato K
Thorac Cancer; 2022 Oct; 13(19):2776-2785. PubMed ID: 36062426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
